Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross- sectional survey in Northwest Ethiopia

References

• Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduction Targeted Ther. 2020;5(1):1–9. doi:10.1038/s41392-020-00352-y.
   PubMed Web of Science ®Google Scholar
• Holder J Tracking coronavirus vaccinations around the world. The New York Times. 2021;30.
   Google Scholar
• Organization WH. Ethiopia launches a COVID-19 vaccination campaign targeting the 12 years and above population. 2021 November 25.
   Google Scholar
• Doroftei B, Ciobica A, Ilie O-D, Maftei R, Ilea C. Mini-Review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics. 2021;11(4):579. doi:10.3390/diagnostics11040579.
   Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Bhatta M, Nandi S, Dutta S, and Saha MK. Coronavirus (SARS-CoV-2): A systematic review for potential vaccines. Hum Vaccines Immunother . 2021;18(1):1865774.
   PubMed Web of Science ®Google Scholar
• Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. Jama. 2021;325(21):2201–2202. doi:10.1001/jama.2021.5374.
   PubMed Web of Science ®Google Scholar
• Kimmel SR. Vaccine adverse events: Separating myth from reality. Am Fam Physician. 2002;66:2113.
   PubMed Web of Science ®Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–593. doi:10.1038/s41586-020-2639-4.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, and Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med . 2020;384:403–416.
   Web of Science ®Google Scholar
• Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: A prospective observational study. Lancet Infect Dis. 2021;21(7):939–949. doi:10.1016/S1473-3099(21)00224-3.
   PubMed Web of Science ®Google Scholar
• Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, Singh K, Yadav D, Sharma P, Misra S, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427–439. doi:10.1007/s12291-021-00968-z.
   PubMed Web of Science ®Google Scholar
• Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, Nourwali I, Qasem F, Dar-Odeh N. Side effects reported by Jordanian healthcare workers who received COVID-19 vaccines. Vaccines. 2021;9(6):577. doi:10.3390/vaccines9060577.
   Web of Science ®Google Scholar
• Hunter PR. Thrombosis after covid-19 vaccination. Bmj. 2021:n958. doi:10.1136/bmj.n958.
   PubMedGoogle Scholar
• Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV -2 vaccination. Am J Hematol. 2021;96(5):534–537. doi:10.1002/ajh.26132.
   PubMed Web of Science ®Google Scholar
• Zhongming Z, Linong L, Xiaona Y, Wangqiang Z, Wei L. ‘It’Sa very special picture.’why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine. 2021.
   Google Scholar
• Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdox1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101. doi:10.1056/NEJMoa2104840.
   PubMed Web of Science ®Google Scholar
• Tobaiqy M, Elkout H, MacLure K. Analysis of thrombotic adverse reactions of COVID-19 AstraZeneca vaccine reported to EudraVigilance database. Vaccines. 2021;9(4):393. doi:10.3390/vaccines9040393.
   PubMed Web of Science ®Google Scholar
• Wolf ME, Luz B, Niehaus L, Bhogal P, Bäzner H, Henkes H. Thrombocytopenia and intracranial venous sinus thrombosis after “COVID-19 vaccine AstraZeneca” exposure. J Clin Med. 2021;10(8):1599. doi:10.3390/jcm10081599.
   PubMed Web of Science ®Google Scholar
• Sing CW, Tang CTL, Chui CSL, Fan M, Lai FTT, Li X, Wan EYF, Wong CKH, Chan EWY, Hung IFN, et al. COVID -19 vaccines and risks of hematological abnormalities: Nested case–control and self-controlled case series study. Am J Hematol. 2022;97(4):470–480. doi:10.1002/ajh.26478.
   PubMed Web of Science ®Google Scholar
• Mann R, Sekhon S, and Sekhon S. Drug-Induced liver injury after COVID-19 vaccine. Cureus. 2021;13(7):e16491.
   Web of Science ®Google Scholar
• Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, Rabin R, Vieths S, Agache I, Akdis M, et al. Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives. Allergy. 2021;76(6):1640–1660. doi:10.1111/all.14840.
   PubMed Web of Science ®Google Scholar
• Kirzinger A, Kearney A, Hamel L, Brodie M. Kff/the Washington Post frontline health care workers survey. The Washington Post/KFF Survey Project. 2021.
   Google Scholar
• Meo S, Bukhari I, Akram J, Meo A, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663–1669. doi:10.26355/eurrev_202102_24877.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdox1 nCov-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdox1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Hatmal MM, Al-Hatamleh MA, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, Mohamud R. Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines. 2021;9(6):556. doi:10.3390/vaccines9060556.
   PubMed Web of Science ®Google Scholar
• Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S, Maghfuri A, Algaissi A. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. 2021;9(6):674. doi:10.3390/vaccines9060674.
   PubMed Web of Science ®Google Scholar
• Camacho Moll ME, Salinas Martínez AM, Tovar Cisneros B, García Onofre JI, Navarrete Floriano G, Bermúdez de León M. Extension and severity of self-reported side effects of seven COVID-19 vaccines in Mexican population. Front Public Health. 2022;10:834744. doi:10.3389/fpubh.2022.834744.
   PubMed Web of Science ®Google Scholar
• Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, Abbas H, Rababah L, Rabadi M, Karasneh R, et al. Reported COVID-19 vaccines side effects among Jordanian population: A cross sectional study. Hum Vaccines Immunother. 2022;18(1):1981086. doi:10.1080/21645515.2021.1981086.
   PubMed Web of Science ®Google Scholar
• Canas LS, Österdahl MF, Deng J, Hu C, Selvachandran S, Polidori L, May A, Molteni E, Murray B, Chen L, et al. Disentangling post-vaccination symptoms from early COVID-19. EClinicalMedicine. 2021;42:101212. doi:10.1016/j.eclinm.2021.101212.
   PubMedGoogle Scholar
• Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr: Clin Res Rev. 2021;15(5):102207. doi:10.1016/j.dsx.2021.102207.
   PubMed Web of Science ®Google Scholar
• Riad A, Jouzová A, Üstün B, Lagová E, Hruban L, Janků P, Pokorná A, Klugarová J, Koščík M, Klugar M, et al. COVID-19 vaccine acceptance of Pregnant and Lactating Women (PLW) in Czechia: an analytical cross-sectional study. Int J Environ Res Public Health. 2021;18(24):13373. doi:10.3390/ijerph182413373.
   PubMed Web of Science ®Google Scholar
• Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854. doi:10.1016/S0140-6736(20)31208-3.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. Jama. 2020;324(10):951–960. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Adam M, Gameraddin M, Alelyani M, Alshahrani MY, Gareeballah A, Ahmad I, Azzawi A, Komit B, Musa A. Evaluation of post-vaccination symptoms of two common COVID-19 vaccines used in Abha, Aseer Region, Kingdom of Saudi Arabia. patient Preference Adherence. 2021;15:1963. doi:10.2147/PPA.S330689.
   PubMed Web of Science ®Google Scholar
• Mahallawi WH, Mumena WA. Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines. Front Immunol. 2021;12:5169. doi:10.3389/fimmu.2021.794642.
   Web of Science ®Google Scholar
• Organization WH. Interim recommendations for use of the ChAdox1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). 2021 [Accessed 2021 May 21].
   Google Scholar
• Mohammed RA, Garout RM, Wahid S, Ayub F, ZinAlddin LMF, and Sultan I. A survey on the side effects of Pfizer/BioNTech COVID-19 vaccine among vaccinated adults in Saudi Arabia. Cureus. 2021;13(11):e19222.
   Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdox1 nCov-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, Zhang B, Licata C, Clark TA, Shimabukuro TT. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):680–684. doi:10.15585/mmwr.mm7018e2.
   PubMed Web of Science ®Google Scholar
• Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Network Open. 2021;4(12): e2140364-e. doi:10.1001/jamanetworkopen.2021.40364.
   Web of Science ®Google Scholar
• Alghamdi A, Ibrahim A, Almutairi R, Joseph M, Alghamdi G, and Alhamza A. A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: Male versus female outcomes. J Adv Pharm Educ Res. 2021 Apr-Jun;11(2):51–56.
   Google Scholar
• Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, Conti L, De Virgilio A, De Marco F, Di Domenico EG, et al. Obesity may hamper SARS-CoV-2 vaccine immunogenicity. MedRxiv. 2021.
   Google Scholar
• Flanagan KL, Fink AL, Plebanski M, Klein SL. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33(1):577–599. doi:10.1146/annurev-cellbio-100616-060718.
   PubMed Web of Science ®Google Scholar
• Voigt EA, Ovsyannikova IG, Kennedy RB, Grill DE, Goergen KM, Schaid DJ, Poland GA. Sex differences in older adults’ immune responses to seasonal influenza vaccination. Front Immunol. 2019;10:180. doi:10.3389/fimmu.2019.00180.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, Caputi A, Rossetti R, Spoltore ME, Filippi V, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465. doi:10.1002/dmrr.3465.
   PubMed Web of Science ®Google Scholar
• Iguacel I, Maldonado AL, Ruiz-Cabello AL, Casaus M, Moreno LA, Martínez-Jarreta B. Association between COVID-19 vaccine side effects and body mass index in Spain. Vaccines. 2021;9(11):1321. doi:10.3390/vaccines9111321.
   Web of Science ®Google Scholar
• Mohammad S, Aziz R, Al Mahri S, Malik SS, Haji E, Khan AH, Khatlani TS, Bouchama A. Obesity and COVID-19: What makes obese host so vulnerable? Immun Ageing. 2021;18(1):1–10. doi:10.1186/s12979-020-00212-x.
   PubMed Web of Science ®Google Scholar
• Andersen CJ, Murphy KE, Fernandez ML. Impact of obesity and metabolic syndrome on immunity. Adv Nutr. 2016;7(1):66–75. doi:10.3945/an.115.010207.
   PubMed Web of Science ®Google Scholar
• McLarnon A. Influenza immunity impaired in obesity. Nat Rev Endocrinol. 2012;8(1):3. doi:10.1038/nrendo.2011.199.
   Google Scholar
• Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33(36):4422–4429. doi:10.1016/j.vaccine.2015.06.101.
   PubMed Web of Science ®Google Scholar
• Ross R, Neeland IJ, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, et al. Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity. Nat Rev Endocrinol. 2020;16(3):177–189. doi:10.1038/s41574-019-0310-7.
   PubMed Web of Science ®Google Scholar
• Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981–984. doi:10.1038/s41591-021-01325-6.
   PubMed Web of Science ®Google Scholar
• Bauernfeind S, Salzberger B, Hitzenbichler F, Scigala K, Einhauser S, Wagner R, Gessner A, Koestler J, Peterhoff D. Association between reactogenicity and immunogenicity after vaccination with BNT162b2. Vaccines. 2021;9(10):1089. doi:10.3390/vaccines9101089.
   PubMed Web of Science ®Google Scholar
• Powell AA, Power L, Westrop S, McOwat K, Campbell H, Simmons R, Ramsay ME, Brown K, Ladhani SN, Amirthalingam G, et al. Real-World data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England. Eurosurveillance. 2021;26(28):2100634. doi:10.2807/1560-7917.ES.2021.26.28.2100634.
   Web of Science ®Google Scholar
• Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. Self-Reported real-world safety and reactogenicity of COVID-19 vaccines: A vaccine recipient survey. Life. 2021;11(3):249. doi:10.3390/life11030249.
   PubMedGoogle Scholar
• Andrzejczak-Grządko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25(12):4418–4421. doi:10.26355/eurrev_202106_26153.
   PubMed Web of Science ®Google Scholar
• Coppeta L, Ferrari C, Somma G, Mazza A, D’Ancona U, Marcuccilli F, Grelli S, Aurilio MT, Pietroiusti A, Magrini A, et al. Reduced titers of circulating anti-SARS-CoV-2 antibodies and risk of COVID-19 infection in healthcare workers during the Nine Months after immunization with the BNT162b2 mRNA vaccine. Vaccines. 2022;10(2):141. doi:10.3390/vaccines10020141.
   PubMed Web of Science ®Google Scholar
• Abebe EC, Dejenie TA, Ayele TM, Admasu FT, Muche ZT, Adela GA. Mutational pattern, impacts and potential preventive strategies of omicron SARS-CoV-2 variant infection. Infect Drug Resist. 2022;15:1871. doi:10.2147/IDR.S360103.
   PubMed Web of Science ®Google Scholar